Company Filing History:
Years Active: 2009
Title: Exploring the Innovations of Marco Riedel
Introduction
Marco Riedel is an accomplished inventor based in Berlin, Germany, known for his significant contributions to the field of bioreactor technology. With a focus on improving cell culturing methods, Riedel has developed a unique approach that enhances the growth and cultivation of cells through innovative designs.
Latest Patents
Riedel's most notable patent is a "Liquid-gas-phase exposure reactor for cell culturing." This invention proposes a novel bioreactor design that consists of culture compartments formed by hollow-filament membranes, which have an inner diameter of no larger than 5 mm. The bioreactor operates by introducing cells into these compartments, where the initiation of growth and cultivation can be controlled through the simultaneous or separate perfusion of a nutrient medium and a gas mixture. This groundbreaking approach allows for cyclic exposure of cells to different phases, significantly advancing the efficiency of cell culture techniques.
Career Highlights
Currently, Marco Riedel is affiliated with Probiogen AG, a company that specializes in biopharmaceutical development and manufacturing. His work at Probiogen AG reflects his commitment to enhancing biotechnological applications and pushing the boundaries of innovation in cell culture technologies.
Collaborations
Throughout his career, Riedel has collaborated with esteemed colleagues such as Uwe Marx and Hikmat Bushnaq-Josting. Together, they contribute to the advancement of research and development within their field, leveraging their expertise to create complex solutions for modern biotechnological challenges.
Conclusion
Marco Riedel's contributions to the field of bioreactor technology, especially through his innovative patent, have the potential to revolutionize cell cultivation methods. As he continues to collaborate with leading professionals in the industry at Probiogen AG, his work is expected to play a pivotal role in future advancements in biopharmaceutical research and development.